Surgery Partners’ Earnings Beat and Guidance Hike Could Be a Game Changer for SGRY

• Earlier this week, Surgery Partners reported quarterly revenues and earnings per share that exceeded analysts' expectations and raised its full-year guidance by a wider margin than industry peers.
• This strong operational performance underscores the company's ability to outperform sector challenges, supported by ongoing shifts in outpatient and specialty care trends.
• We’ll explore how Surgery Partners' raised full-year guidance and outperformance deepen the company’s investment case in outpatient surgical care.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Surgery Partners Investment Narrative Recap

To own shares of Surgery Partners, you need confidence in the migration of complex procedures to outpatient settings and the company's ability to capture value from this shift. While the latest quarterly results and raised guidance provided a bump to near-term sentiment, these alone may not fully resolve mid and long-term pressures around debt service and execution on acquisition targets. The short-term catalyst is continued robust earnings surprises, but interest expense growth remains a significant risk that could weigh on cash flow despite strong operational results.

The August 2025 guidance reaffirmation stands out, as Surgery Partners projected US$3.30 billion to US$3.45 billion in revenue for the year, pointing toward management's confidence in sustained growth. This forecast, raised alongside sector peers but with relatively higher ambition, is directly tied to the company’s bet on outpatient growth trends, yet hinges on consistent facility performance and disciplined cost control that will be tested by market headwinds.

Yet, despite these short-term wins, investors should take note of the growing impact of rising interest expenses on earnings and cash generation...

Read the full narrative on Surgery Partners (it's free!)

Surgery Partners' narrative projects $4.3 billion in revenue and $164.3 million in earnings by 2028. This requires 9.9% yearly revenue growth and a rise in earnings of $344.7 million from the current level of -$180.4 million.

Uncover how Surgery Partners' forecasts yield a $31.00 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided two fair value estimates for the stock ranging from US$31.00 to US$79.54. While optimism around guidance lifts the short-term story, wide opinion gaps highlight the importance of considering ongoing risks to cash flow amid Surgery Partners' reliance on debt-financed growth.

Explore 2 other fair value estimates on Surgery Partners - why the stock might be worth just $31.00!

Build Your Own Surgery Partners Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Surgery Partners research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com